New Aquis admission: Can Cardiogeni bounce back?

Cellular medicines developer Cardiogeni (LON: CGNI) joined Aquis at the end of January 2025. The core CLXR-001 product is targeting the cardiac market, specifically coronary artery bypass grafting (CABG).

Cardiogeni floated to increase its profile and attract a broader shareholder base. The share price slumped from the subscription price of 147p to 60p on the first day and the bid/offer spread is 45p/75p. There were no declared trades on the first day of trading. On the second 300 shares were traded, which were two buys of 150 shares at 66p each. Despite that the share price was unchanged ...

Latest News

More Articles Like This